Keywords: Roche, 2010 financial results
Roche posts 11% rise in 2010 net profit but sales down 3%
Article | 02 February 2011
Swiss drug major Roche (ROG: VX) this morning revealed that full-year 2011 net profit rose 11% to 8.67 billion Swiss francs ($9.03 billion), but ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
